Hyeon Tae Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyeon Tae Kang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Dae Won Jun
Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
7 shared publications - Waqar Khalid Saeed
Department of Internal Medicine, Hanyang University School of Medicine, Seoul, South Korea
6 shared publications Jai Sun Lee
Department of Translational Medicine, Hanyang University Graduate school of Biomedical Science and Engineering, Seoul, South Korea
4 shared publications- Kiseok Jang
Department of Pathology, Hanyang University College of Medicine, Seoul 04763, Korea
4 shared publications Yeon Ji Chae
Department of Translational Medicine, Hanyang University Graduate school of Biomedical Science and Engineering, Seoul, South Korea
4 shared publicationsKiseok Jang
Department of Pathology, Hanyang University College of Medicine, Seoul, South Korea
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 920
Comparative Phytochemical Profiling and Phenotypic Senolytic Screening of Botanical Extracts for Oxidative-Stress-Induced Skin-Cell Senescence
Cellular senescence contributes to skin aging through the accumulation of senescent cells and the secretion of senescence-associated secretory phenotype (SASP) factors. Although numerous botanical flavonoids have been reported to possess antioxidant and anti-aging properties, the relationship between phytochemical composition, antioxidant capacity, and senolytic activity in complex botanical extracts remains poorly understood. In this study, twenty botanical extracts were systematically compared using a standardized screening platform that integrated total flavonoid quantification, UPLC-Q-TOF-MS phytochemical profiling, antioxidant evaluation, cytotoxicity assessment, and phenotypic senolytic screening in oxidative-stress-induced human foreskin fibroblast (HFF) senescence models. Among the tested extracts, chlorella, water lily, green tea, and rosemary exhibited the most pronounced senolytic-associated activities while maintaining minimal cytotoxicity toward non-senescent fibroblasts. UPLC-Q-TOF-MS analysis revealed that these extracts possessed distinct flavonoid-enriched phytochemical fingerprints despite producing comparable biological responses. Notably, green tea extract exhibited the strongest antioxidant activity, whereas its phytochemical composition differed substantially from those of the other highly active extracts, indicating that antioxidant capacity alone does not predict senolytic efficacy. Collectively, the findings demonstrate that total flavonoid content, antioxidant activity, and senolytic activity are not necessarily directly correlated and highlight the importance of comprehensive phytochemical characterization combined with phenotypic biological screening for identifying botanical resources with senescence-modulating potential. These results provide a practical comparative strategy for discovering multifunctional botanical ingredients applicable to oxidative-stress-associated skin aging.
- 24 July 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 920
Open AccessComparative Phytochemical Profiling and Phenotypic Senolytic Screening of Botanical Extracts for Oxidative-Stress-Induced Skin-Cell Senescence
Cellular senescence contributes to skin aging through the accumulation of senescent cells and the secretion of senescence-associated secretory phenotype (SASP) factors. Although numerous botanical flavonoids have been reported to possess antioxidant and anti-aging properties, the relationship between phytochemical composition, antioxidant capacity, and senolytic activity in complex botanical extracts remains poorly understood. In this study, twenty botanical extracts were systematically compared using a standardized screening platform that integrated total flavonoid quantification, UPLC-Q-TOF-MS phytochemical profiling, antioxidant evaluation, cytotoxicity assessment, and phenotypic senolytic screening in oxidative-stress-induced human foreskin fibroblast (HFF) senescence models. Among the tested extracts, chlorella, water lily, green tea, and rosemary exhibited the most pronounced senolytic-associated activities while maintaining minimal cytotoxicity toward non-senescent fibroblasts. UPLC-Q-TOF-MS analysis revealed that these extracts possessed distinct flavonoid-enriched phytochemical fingerprints despite producing comparable biological responses. Notably, green tea extract exhibited the strongest antioxidant activity, whereas its phytochemical composition differed substantially from those of the other highly active extracts, indicating that antioxidant capacity alone does not predict senolytic efficacy. Collectively, the findings demonstrate that total flavonoid content, antioxidant activity, and senolytic activity are not necessarily directly correlated and highlight the importance of comprehensive phytochemical characterization combined with phenotypic biological screening for identifying botanical resources with senescence-modulating potential. These results provide a practical comparative strategy for discovering multifunctional botanical ingredients applicable to oxidative-stress-associated skin aging.
- Open Access
- 1 August 2020
- Published by Acta Scientific Publications Pvt. Ltd. in Acta Scientific Nutritional Health
- Vol. 4 (9) , 42-52
Sericin Peptide Attenuates Non-Alcoholic Steatohepatitis Via Mitochondrial Function Modulation
- 1 August 2020
- Published by Acta Scientific Publications Pvt. Ltd. in Acta Scientific Nutritional Health
- Vol. 4 (9) , 42-52
Open AccessSericin Peptide Attenuates Non-Alcoholic Steatohepatitis Via Mitochondrial Function Modulation
- 27 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (12) , 2206-2218
Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase
Background and Aim: Receptor‐interacting serine/threonine kinase 3 and mixed lineage kinase domain‐like pseudokinase (MLKL) have gained attention as apoptosis alternate cell death signaling molecules. We aimed to evaluate the role of MLKL in non‐alcoholic fatty liver disease (NAFLD).Methods: Hepatic tissue MLKL expression was compared between NAFLD patients and healthy controls. High‐fat diet was fed to wild‐type and MLKL‐knockout (KO) mice for 12 weeks. Brown adipose fat tissue was measured by [18F]‐fluorodeoxyglucose positron emission tomography. Energy expenditure was measured by indirect calorimetry. Anti‐MLKL effects were also evaluated in in vitro setting using U937 and HepG2 cells.Results: Hepatic tissue MLKL expression increased in NAFLD patients compared with healthy controls. MLKL expression increased according to the degree of steatosis, ballooning, and inflammation. High‐fat diet‐fed MLKL‐KO mice displayed decreased alanine aminotransferase, triglycerides, liver weight, NAFLD activity score (6.3 vs 3.5, P < 0.001), steatosis score (3.0 vs 1.8, P < 0.001), inflammation, and ballooning degeneration compared with wild‐type mice. SREBP1c, fatty acid synthase, and SCD‐1 expressions decreased in MLKL‐KO mice. Adipose tissue F4/80‐positive crown‐like structures were also reduced in MLKL‐KO mice. HepG2 cells treated with necrosulfonamide (an MLKL inhibitor) showed reduced Nile red staining and reduced SREBP1c and SCD‐1 expressions. Stimulation of necroptosis using lipopolysaccharide + caspase inhibitor (zVAD) increased CXCL1/2 expressions in U937 monocyte cells. Lipopolysaccharide + zVAD‐induced increased expressions of CXCL1/2 were reduced with necrosulfonamide treatment.Conclusions: Mixed lineage kinase domain‐like pseudokinase inhibition has protective effects in non‐alcoholic steatohepatitis by decreasing hepatic de novo fat synthesis and chemokine (C‐X‐C motif) ligand expressions.
- 27 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (12) , 2206-2218
Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase
Background and Aim: Receptor‐interacting serine/threonine kinase 3 and mixed lineage kinase domain‐like pseudokinase (MLKL) have gained attention as apoptosis alternate cell death signaling molecules. We aimed to evaluate the role of MLKL in non‐alcoholic fatty liver disease (NAFLD).Methods: Hepatic tissue MLKL expression was compared between NAFLD patients and healthy controls. High‐fat diet was fed to wild‐type and MLKL‐knockout (KO) mice for 12 weeks. Brown adipose fat tissue was measured by [18F]‐fluorodeoxyglucose positron emission tomography. Energy expenditure was measured by indirect calorimetry. Anti‐MLKL effects were also evaluated in in vitro setting using U937 and HepG2 cells.Results: Hepatic tissue MLKL expression increased in NAFLD patients compared with healthy controls. MLKL expression increased according to the degree of steatosis, ballooning, and inflammation. High‐fat diet‐fed MLKL‐KO mice displayed decreased alanine aminotransferase, triglycerides, liver weight, NAFLD activity score (6.3 vs 3.5, P < 0.001), steatosis score (3.0 vs 1.8, P < 0.001), inflammation, and ballooning degeneration compared with wild‐type mice. SREBP1c, fatty acid synthase, and SCD‐1 expressions decreased in MLKL‐KO mice. Adipose tissue F4/80‐positive crown‐like structures were also reduced in MLKL‐KO mice. HepG2 cells treated with necrosulfonamide (an MLKL inhibitor) showed reduced Nile red staining and reduced SREBP1c and SCD‐1 expressions. Stimulation of necroptosis using lipopolysaccharide + caspase inhibitor (zVAD) increased CXCL1/2 expressions in U937 monocyte cells. Lipopolysaccharide + zVAD‐induced increased expressions of CXCL1/2 were reduced with necrosulfonamide treatment.Conclusions: Mixed lineage kinase domain‐like pseudokinase inhibition has protective effects in non‐alcoholic steatohepatitis by decreasing hepatic de novo fat synthesis and chemokine (C‐X‐C motif) ligand expressions.
- Open Access
- 17 April 2019
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 13 (4) , 450-460
The Use of Foxa2-Overexpressing Adipose Tissue-Derived Stem Cells in a Scaffold System Attenuates Acute Liver Injury
Yeon Ji Chae, Dae Won Jun, Jai Sun Lee, Waqar Khalid Saeed, Hyeon Tae Kang, Kiseok Jang, and Jin Ho Lee. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18235
- 17 April 2019
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 13 (4) , 450-460
Open AccessThe Use of Foxa2-Overexpressing Adipose Tissue-Derived Stem Cells in a Scaffold System Attenuates Acute Liver Injury
Yeon Ji Chae, Dae Won Jun, Jai Sun Lee, Waqar Khalid Saeed, Hyeon Tae Kang, Kiseok Jang, and Jin Ho Lee. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18235
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14
- 1 January 2019
- Published by XMLink in Journal of Korean Medical Science
- Vol. 34 (2) , e14
Open AccessFeasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
Chae YJ, et al. J Korean Med Sci. 2018 Dec;34(2):e14. https://doi.org/10.3346/jkms.2019.34.e14
- 12 November 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (3) , 781-791
Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold
Background Injecting MSCs via blood vessel is most commonly used method, which has a major drawback of safety. The aim of our study was to evaluate efficacy using scaffold-loaded MSCs in acute liver failure model. Method Acute liver failure was induced in mice using thioacetamide (TAA) (200 mg/kg, i.p) once a day for two consecutive days. The animals were divided in four acute liver failure groups: (1) TAA; (2) empty scaffold; (3) MSCs injected through tail vein; (4) MSC + Scaffold, scaffold loaded with MSCs, to evaluate the mortality and changes in liver function. Polylactic-co-glycolic acid scaffold alone and loaded with human MSCs was implanted on mice dorsum. Results TAA dose was titrated until one-third mortality rate was achieved. TAA (200 mg/kg) once daily for two consecutive days was injected to establish the acute liver failure model. The mortality of TAA and scaffold groups was 55.9% and 63.2%, respectively. Although, mortality of MSC-TV group decreased 14.7% as compared to TAA group (p = 0.200), MSC + Scaffold group had the lowest mortality (31.4%) (p = 0.013). Cells implanted in PLGA biomaterial were survived until 3 weeks, and their function was increased. Area of hepatic inflammation and necrosis was significantly reduced in MSC-TV and MSC + Scaffold groups; but there was no difference between the two groups. Gene expressions related to inflammation were significantly decreased in MSC-TV and MSC + Scaffold groups compared to TAA group. In MSC + Scaffold group, no migration of stem cells to liver tissue was observed. Although, not all cells in scaffold were stained, some of them were differentiated into hepatocyte-like cells which stained positive for PAS and CYP2E1 antibody. Conclusion Scaffold loaded with MSCs showed protective effects via paracrine signaling on acute liver failure model.
- 12 November 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (3) , 781-791
Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold
Background Injecting MSCs via blood vessel is most commonly used method, which has a major drawback of safety. The aim of our study was to evaluate efficacy using scaffold-loaded MSCs in acute liver failure model. Method Acute liver failure was induced in mice using thioacetamide (TAA) (200 mg/kg, i.p) once a day for two consecutive days. The animals were divided in four acute liver failure groups: (1) TAA; (2) empty scaffold; (3) MSCs injected through tail vein; (4) MSC + Scaffold, scaffold loaded with MSCs, to evaluate the mortality and changes in liver function. Polylactic-co-glycolic acid scaffold alone and loaded with human MSCs was implanted on mice dorsum. Results TAA dose was titrated until one-third mortality rate was achieved. TAA (200 mg/kg) once daily for two consecutive days was injected to establish the acute liver failure model. The mortality of TAA and scaffold groups was 55.9% and 63.2%, respectively. Although, mortality of MSC-TV group decreased 14.7% as compared to TAA group (p = 0.200), MSC + Scaffold group had the lowest mortality (31.4%) (p = 0.013). Cells implanted in PLGA biomaterial were survived until 3 weeks, and their function was increased. Area of hepatic inflammation and necrosis was significantly reduced in MSC-TV and MSC + Scaffold groups; but there was no difference between the two groups. Gene expressions related to inflammation were significantly decreased in MSC-TV and MSC + Scaffold groups compared to TAA group. In MSC + Scaffold group, no migration of stem cells to liver tissue was observed. Although, not all cells in scaffold were stained, some of them were differentiated into hepatocyte-like cells which stained positive for PAS and CYP2E1 antibody. Conclusion Scaffold loaded with MSCs showed protective effects via paracrine signaling on acute liver failure model.
- Open Access
- 28 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0184752
Does necroptosis have a crucial role in hepatic ischemia-reperfusion injury?
Previous studies have demonstrated protective effects of anti-receptor interacting protein kinase 1 (RIP1), a key necroptosis molecule. However, it is uncertain whether necroptosis has a crucial role in hepatic IR injury. Therefore, we evaluated the role of necroptosis in hepatic IR injury. The IR mice underwent 70% segmental IR injury induced by the clamping of the hepatic artery and portal vein for 1 hr followed by reperfusion for 4 hr. The key necroptosis molecules (RIP1, RIP3, and MLKL) and other key molecules of regulated necrosis (PGAM5 and caspase-1) were evaluated in the warm IR injury model. A RIP1 inhibitor (necrostain-1s) and/or an anti-mitochondrial permeability transition (MPT)-mediated necrosis mediator (cyclosporine A, CyA) were administered before clamping. Necrotic injury was quantified using Suzuki’s scoring system. qRT-PCR and western blot were performed to evaluate RIP1, RIP3, MLKL and PGAM5 expressions. RIP1, RIP3, MLKL and PGAM5 expression did not change in the hepatic IR injury model. Moreover, Nec1s pretreatment did not improve histology or biochemical markers. The overall Suzuki score (cytoplasmic vacuolization, sinusoidal congestion and hepatocytes necrosis) was increased in the RIP3(-/-) mice compared to the IR group (3.5 vs. 5, p = 0.026). CyA pretreatment and/or RIP3(-/-) mice decreased Bax/Bcl2 expression; however, it did lead to an overall change in the levels of AST, ALT and LDH or necrotic injury. The Bax/Bcl2 ratio and the expression of caspase-1 and caspase-3 did not increase in our hepatic IR injury model. Key necroptosis molecules did not increase in the necrosis-dominant hepatic IR injury model. Anti-necroptosis and/or cyclosporine-A treatment did not have an overall protective effect on necrosis-dominant hepatic IR injury.
- 28 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0184752
Open AccessDoes necroptosis have a crucial role in hepatic ischemia-reperfusion injury?
Previous studies have demonstrated protective effects of anti-receptor interacting protein kinase 1 (RIP1), a key necroptosis molecule. However, it is uncertain whether necroptosis has a crucial role in hepatic IR injury. Therefore, we evaluated the role of necroptosis in hepatic IR injury. The IR mice underwent 70% segmental IR injury induced by the clamping of the hepatic artery and portal vein for 1 hr followed by reperfusion for 4 hr. The key necroptosis molecules (RIP1, RIP3, and MLKL) and other key molecules of regulated necrosis (PGAM5 and caspase-1) were evaluated in the warm IR injury model. A RIP1 inhibitor (necrostain-1s) and/or an anti-mitochondrial permeability transition (MPT)-mediated necrosis mediator (cyclosporine A, CyA) were administered before clamping. Necrotic injury was quantified using Suzuki’s scoring system. qRT-PCR and western blot were performed to evaluate RIP1, RIP3, MLKL and PGAM5 expressions. RIP1, RIP3, MLKL and PGAM5 expression did not change in the hepatic IR injury model. Moreover, Nec1s pretreatment did not improve histology or biochemical markers. The overall Suzuki score (cytoplasmic vacuolization, sinusoidal congestion and hepatocytes necrosis) was increased in the RIP3(-/-) mice compared to the IR group (3.5 vs. 5, p = 0.026). CyA pretreatment and/or RIP3(-/-) mice decreased Bax/Bcl2 expression; however, it did lead to an overall change in the levels of AST, ALT and LDH or necrotic injury. The Bax/Bcl2 ratio and the expression of caspase-1 and caspase-3 did not increase in our hepatic IR injury model. Key necroptosis molecules did not increase in the necrosis-dominant hepatic IR injury model. Anti-necroptosis and/or cyclosporine-A treatment did not have an overall protective effect on necrosis-dominant hepatic IR injury.
- Open Access
- 4 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (58) , 97965-97976
Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
- 4 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (58) , 97965-97976
Open AccessGranulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization